Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

Keyphrases

• Coagulation Disorders 100%
• Interferon-α (IFN-α) 100%
• AIDS/HIV 100%
• Chronic Hepatitis C 100%
• Infected Patients 100%
• Ribavirin 100%
• Combination Therapy 100%
• Hemophiliacs 50%
• MRNA Level 33%
• Hepatitis C Virus 33%
• Hepatitis C Virus RNA 33%
• Highly Active Antiretroviral Therapy (HAART) 33%
• CD4+ 16%
• Clinical Follow-up 16%
• Sustained Virological Response 16%
• Thrice Weekly 16%
• Non-responders 16%
• Virus Replication 16%
• Dose Adjustment 16%
• Virus RNA 16%
• Treatment Withdrawal 16%
• Cell Count 16%
• CD4 Count 16%
• Dose Reduction 16%
• Virological Response 16%
• Interferon alpha-2b 16%

Pharmacology, Toxicology and Pharmaceutical Science

• HIV 100%
• Combination Therapy 100%
• Chronic Hepatitis C 100%
• Interferon 100%
• Ribavirin 100%
• Blood Clotting Disorder 100%
• Hepatitis C Virus 66%
• Virus RNA 50%
• Side Effect 16%
• Alpha2b Interferon 16%

Immunology and Microbiology

• Interferon Type I 100%
• Human Immunodeficiency Virus 100%
• Hepatitis C 100%
• Ribavirin 100%
• Hepatitis C Virus 66%
• RNA Virus 50%
• CD4 Lymphocyte Count 33%
• Viral Replication 16%
• Drug Dose Reduction 16%
• Alpha2b Interferon 16%